Search results
Results From The WOW.Com Content Network
Treatment for CMV infection should start at 1 month of age and should occur for 6 months. The options for treatment are intravenous ganciclovir and oral valganciclovir. After diagnosis, it is important to further investigate any possible evidence of end-organ disease and symptoms through blood tests, imaging, ophthalmology tests, and hearing tests.
TORCH syndrome is a cluster of symptoms caused by congenital infection with toxoplasmosis, rubella, cytomegalovirus, herpes simplex, and other organisms including syphilis, parvovirus, and Varicella zoster. [1] Zika virus is considered the most recent member of TORCH infections. [2]
The 11 species in this genus include human betaherpesvirus 5 (HCMV, human cytomegalovirus, HHV-5), which is the species that infects humans. Diseases associated with HHV-5 include mononucleosis and pneumonia, [4] [5] and congenital CMV in infants can lead to deafness and ambulatory problems. [6]
Most commonly, valganciclovir or ganciclovir are used as first-line antiviral therapy for congenital CMV. [11] If the cause is a malignancy, the patient should receive cancer treatment such as chemotherapy. [6] Overall, treatment of the blueberry muffin baby is centered around the underlying cause.
Cytomegalic inclusion body disease (CIBD) also known as cytomegalic inclusion disease (CID) is a series of signs and symptoms caused by cytomegalovirus infection, toxoplasmosis or other rare infections such as herpes or rubella viruses. It can produce massive calcification of the central nervous system, and often the kidneys. [1]
Trenace Dorsey-Hollins’ 5-year-old daughter was sick a lot last year. Dorsey-Hollins followed school guidelines and kept her home when she had a cough or a sore throat — or worse — until she ...
CMV placentitis. When physical examination of the newborn shows signs of a vertically transmitted infection, the examiner may test blood, urine, and spinal fluid for evidence of the infections listed above. Diagnosis can be confirmed by culture of one of the specific pathogens or by increased levels of IgM against the pathogen. [citation needed]
Specific treatment options for HHV-6, 7, and 8 are currently in the early stages of development. Some research suggests that acyclovir and anti-CMV drugs such as cidofovir and foscarnet may have some therapeutic benefit in HHV-7 infection.